Evommune says EVO756 phase 2b failed in atopic dermatitis
Evommune said EVO756 in moderate-to-severe atopic dermatitis did not meet primary or secondary endpoints and will be discontinued for AD.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.